Rutgers Cancer Institute | Strategic Alliance Partners

December 13, 2021

Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 2021 ASH Annual Meeting and Exposition.

December 07, 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

December 06, 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

December 02, 2021

Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.

December 01, 2021

Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in tumor sequencing assays to predict the origin of detected DNA alterations.

November 23, 2021

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

November 23, 2021

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

November 23, 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

November 22, 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

November 22, 2021

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

November 18, 2021

Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.

November 18, 2021

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer.

November 18, 2021

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

November 18, 2021

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

November 18, 2021

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.

November 11, 2021

Chemotherapy has demonstrated mixed findings in patients with resectable colorectal hepatic metastases, and long-term data suggest incorporating it into treatment algorithms have little impact on overall survival.

November 02, 2021

Salma K. Jabbour, MD, discusses the validity and clinical implications of using pembrolizumab plus platinum chemoradiation in patients with stage III non–small cell lung cancer.

August 09, 2021

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

August 05, 2021

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

July 27, 2021

As the State’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey will lead this effort.